#151589

Anti-SIGLEC5 [1A5]

Cat. #151589

Anti-SIGLEC5 [1A5]

Cat. #: 151589

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 1-2 weeks

Target: Siglec5

Class: Monoclonal

Application: IHC ; ELISA ; FACS ; IHC ; IF ; IP ; Fn ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Paul Crocker

Institute: University of Dundee

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-SIGLEC5 [1A5]
  • Alternate name: Sialic Acid Binding Ig Like Lectin 5; Obesity-Binding Protein 2; OB-Binding Protein 2; CD33 Antigen-Like 2; SIGLEC-5; CD33L2; OBBP2; Sialic Acid-Binding Immunoglobulin-Like Lectin 5; CD17 Antigen;
  • Clone: 1A5
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC ; ELISA ; FACS ; IHC ; IF ; IP ; Fn ; WB
  • Description: The Siglecs are a family of membrane bound lectins (of the immunoglobulin superfamily) that bind sialic acid and mediate cell-cell interactions. Siglec5 (CD170) is a member of the recently-described human CD33-related siglec subgroup of sialic acid binding Ig-like lectins and is expressed on myeloid cells of the hemopoietic system. Similar to other CD33- related siglecs, Siglec-5 contains two tyrosine based motifs in its cytoplasmic tails implicated in signalling functions. The antibody cross reacts with Siglec14.
  • Immunogen: Siglec-5-Fc protein, containing entire extracellular region of siglec-5 fused with the Fc region of human IgG1
  • Isotype: IgG1
  • Myeloma used: Sp2/0-Ag14
  • Recommended controls: Siglec5 transfected CHO cells. Apart from Siglec14 (Angata T et al. 2006 FASEB J. 20:1964-73. PMID: 17012248), non-cross-reactive with panel of other Siglec proteins, either expressed on CHO cells or as recombinant proteins.

Target Details

  • Target: Siglec5
  • Tissue cell line specificity: Siglec5 transfected CHO cells. Apart from Siglec14 (Angata T et al. 2006 FASEB J. 20:1964-73. PMID: 17012248), non-cross-reactive with panel of other Siglec proteins, either expressed on CHO cells or as recombinant proteins.
  • Target background: The Siglecs are a family of membrane bound lectins (of the immunoglobulin superfamily) that bind sialic acid and mediate cell-cell interactions. Siglec5 (CD170) is a member of the recently-described human CD33-related siglec subgroup of sialic acid binding Ig-like lectins and is expressed on myeloid cells of the hemopoietic system. Similar to other CD33- related siglecs, Siglec-5 contains two tyrosine based motifs in its cytoplasmic tails implicated in signalling functions. The antibody cross reacts with Siglec14.

Applications

  • Application: IHC ; ELISA ; FACS ; IHC ; IF ; IP ; Fn ; WB

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -80° C
  • Shipping conditions: Shipping at 4° C

References

  • Angata et al. 2006. FASEB J. 20(12):1964-73. PMID: 17012248.
  • Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates.
  • Nguyen et al. 2006. Proc Natl Acad Sci U S A. 103(20):7765-70. PMID: 16682635.
  • Loss of Siglec expression on T lymphocytes during human evolution.
  • Avril et al. 2005. J Biol Chem. 280(20):19843-51. PMID: 15769739.
  • Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation.
  • Connolly et al. 2002. Br J Haematol. 119(1):221-38. PMID: 12358929
  • Human Siglec-5: tissue distribution, novel isoforms and domain specificities for sialic acid-dependent ligand interactions.
  • Cornish et al. 1998. Blood. 92(6):2123-32. PMID: 9731071.
  • Characterization of siglec-5, a novel glycoprotein expressed on myeloid cells related to CD33.